Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.

Grade Last Price % Change Price Change
grade A 25.78 5.31% 1.30
IOVA closed up 5.31 percent on Thursday, July 18, 2019, on 80 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Aug 6

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical IOVA trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
New 52 Week High Strength 0.00%
Stochastic Reached Overbought Strength 0.00%
Overbought Stochastic Strength 0.00%
New 52 Week Closing High Bullish 3.78%
Down 3 Days in a Row Weakness 7.82%
1,2,3 Pullback Bullish Bullish Swing Setup 7.73%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 7.73%

Older signals for IOVA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Medicine Biopharmaceutical Cancer Clinical Medicine Oncology Immunotherapy Cancer Treatments Cancer Immunotherapy Antineoplastic Drugs Melanoma Cell Therapy Solid Tumor Metastatic Melanoma Adoptive Cell Transfer Cancer Immunotherapy Products Head And Neck Cancers Breast And Lung Cancer National Cancer Institute Ocular Melanoma Treatment Of Metastatic Melanoma
Is IOVA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.0689
52 Week Low 7.26
Average Volume 2,227,941
200-Day Moving Average 12.3359
50-Day Moving Average 19.4942
20-Day Moving Average 23.6915
10-Day Moving Average 24.481
Average True Range 1.2204
ADX 45.05
+DI 29.1668
-DI 12.7573
Chandelier Exit (Long, 3 ATRs ) 22.4077
Chandelier Exit (Short, 3 ATRs ) 24.2912
Upper Bollinger Band 26.2839
Lower Bollinger Band 21.0991
Percent B (%b) 0.9
BandWidth 21.884642
MACD Line 1.5224
MACD Signal Line 1.6743
MACD Histogram -0.1519
Fundamentals Value
Market Cap 1.84 Billion
Num Shares 71.5 Million
EPS -2.08
Price-to-Earnings (P/E) Ratio -12.39
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.36
Resistance 3 (R3) 28.17 27.12 27.93
Resistance 2 (R2) 27.12 26.46 27.21 27.79
Resistance 1 (R1) 26.45 26.06 26.78 26.64 27.64
Pivot Point 25.40 25.40 25.57 25.49 25.40
Support 1 (S1) 24.73 24.74 25.07 24.92 23.92
Support 2 (S2) 23.68 24.34 23.78 23.77
Support 3 (S3) 23.01 23.68 23.63
Support 4 (S4) 23.20